MSMargherita Serra

Margherita Serra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Margherita Serra has a total of 91 co-authors. Here are the top co-authors by number of shared publications:

  • Alice Pellegrini

    Breast Surgery Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

    2 shared publications
  • Marco Bernini

    Breast Surgery Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

    2 shared publications
  • Marica Melina

    Breast Surgery Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

    2 shared publications
  • Mario Taffurelli

    UOC di Chirurgia Generale e Della Mammella Policlinico di Sant'Orsola, Università di Bologna, Bologna, Italy

    2 shared publications
  • Simone Zanotti

    Breast Surgery Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

    2 shared publications
  • A. Quattrini Li

    Centro Senologico Azienda Ospedaliera Universitaria Pisana Ospedale Santa Chiara, Pisa, Italy

    1 shared publication

Latest Publications

  • Open Access

    Bilateral risk reducing mastectomy uptake trends in healthy BRCA1/2 mutation carriers of an European City, the brachoice study

    by Marco Bernini, Sofia Innocenti, Daniela Turchetti, Sara Miccoli, Giovanni Innella, Alice Pellegrini, Marica Melina, Simone Zanotti, Maria Cristina Cucchi, Valentina Galluzzo, et al.

    This study evaluates the uptake of bilateral risk-reducing mastectomy (BRRM) among unaffected BRCA1/2 mutation carriers in the metropolitan area of Bologna, Italy, between 2012 and 2024. Pathogenic BRCA variants, which confer a markedly increased lifetime risk of breast cancer, are managed through preventive strategies such as BRRM, which can reduce risk by more than 90%.Among 178 women (89 BRCA1 and 89 BRCA2 carriers), 22.5% elected to undergo BRRM, with a significantly higher uptake among BRCA1 carriers (33.7%) compared with BRCA2 carriers (11.2%). Most procedures were performed more than two years after genetic testing, and the most common age at surgery was 41-45 years.Furthermore, the results demonstrate a progressive increase over time in both genetic testing and BRRM uptake, in line with international trends. However, the observed rates remain lower than those reported in Northern Europe. Despite limitations related to cohort size and data completeness, this study provides updated evidence on decision-making regarding BRRM among Italian women at hereditary risk of breast cancer.

  • Open Access

    Breast Cancer and Ovarian Tissue Cryopreservation: SWOT Analysis

    by Diego Raimondo, Marisol Doglioli, Cristian Forastiere, Rossella Vicenti, Marco Schirripa, Enrico Pazzaglia, Michele Miscia, Daniele Neola, Linda Bertoldo, Maria Massucci, et al.

    Background/Objectives: Breast cancer is the most common malignancy in young women, many of whom face fertility impairment due to gonadotoxic treatments and prolonged endocrine therapy. Ovarian tissue cryopreservation (OTC) has emerged as an alternative fertility preservation (FP) strategy, particularly when controlled ovarian stimulation is not feasible. This study aimed to evaluate the role of OTC in breast cancer patients, with the aim of clarifying its current clinical role and future perspectives within fertility preservation counselling for this population. Methods: A structured SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis was conducted based on the current literature, addressing clinical efficacy, safety, and applicability of OTC in breast cancer patients. Results: Key strengths of OTC include the absence of delay in cancer treatment and the potential to restore both endocrine and reproductive function. However, limitations include the need for surgery, the theoretical risk of reintroducing malignant cells, and variable, less predictable reproductive outcomes compared with gamete-based strategies. Opportunities lie in advances in cryopreservation, transplantation techniques, and integration with in vitro maturation. Major threats include limited data in breast cancer-specific populations, challenges in BRCA mutation carriers, and low utilization rates affecting cost-effectiveness and healthcare sustainability. Conclusions: OTC represents a valuable complementary FP option for selected breast cancer patients, particularly in urgent settings. Despite promising outcomes, its use should remain individualized within multidisciplinary counseling, considering patient-specific oncological and reproductive factors, while further research is needed to clarify long-term safety and efficacy.


  • Open Access

    Selective Pectoralis Muscle Denervation Reduces Capsular Contracture in Sub‐Pectoral Breast Reconstruction. Long‐Term Retrospective Case‐ Control Study

    by Marco Bernini, Federico Spolveri, Margherita Serra, Silvia Sordi, Cinzia Tommasi, Lorenzo Orzalesi, Lorenzo Tofani, Chiara Bellini, Diego De Benedetto, Jacopo Nori Cucchiari, et al.

    Background: Implant‐based breast reconstruction (IBBR) is the most common method of breast reconstruction globally. Although the traditional approach places implants in a retropectoral position, pre‐pectoral reconstruction has recently gained popularity due to its improved aesthetic outcomes and lower capsular contracture (CC) rates. However, not all patients are ideal candidates for prepectoral IBBR, making the retropectoral technique still a valuable option. Capsular contracture is a common complication of IBBR, causing discomfort, pain, poor cosmetic results, and often necessitating revision surgery, particularly in retropectoral cases. Selective denervation of the pectoralis major muscle (PMM) in retropectoral IBBR is a novel technique to reduce these complications. Material and Methods: We selected a group of denervated retro‐pec IBBR patients and compared them to non‐denervated patients. In a previous study, we analyzed the subjective opinions on the reconstruction outcomes using the BREAST‐Q postoperative questionnaire. At the same time, we compared retrospectivally the same groups, with a minimum 24‐month follow‐up, from an objective perspective, evaluating CC rates by Baker scale and possible implant malrotation through outpatient clinic visits performed by three independent breast cancer professionals. Results: The overall mean follow‐up was 3.33 (±0.47) years, and the CC rate was significantly lower in Group 1, even adjusting for the propensity score. Conclusions: PMM selective denervation has gained statistical appreciation by women and significantly reduced the CC rate from an objective evaluation in the setting of retro‐pectoral IBBR in our series.


  • Open Access

    5.8S rRNA forms and ribosome heterogeneity in breast cancer

    by Giulia Venturi, Federico Zacchini, Francesca Ruzzi, Angelo Gianluca Corradini, Margherita Serra, Marianna Penzo, Davide Treré, Pier-Luigi Lollini, Lorenzo Montanaro


  • Open Access

    Prognostic Role of p53 Immunohistochemical Status in Invasive Breast Cancer. A Retrospective Review of 1387 Cases With Luminal-Like/Her2 Negative Breast Tumors

    by Gerti Dajti, Margherita Serra, Giovanni Cisternino, Claudio Ceccarelli, Alice Pellegrini, Marica Melina, Antonio De Leo, Donatella Santini, Mario Taffurelli, Simone Zanotti

    Purpose: The aim of this study was to evaluate the prognostic role of p53 immunohistochemical (IHC) expression in a large cohort of patients with hormone receptors (HR)-positive/Her2-negative primary invasive breast cancer. Methods: Retrospective review of consecutive cases treated at our Breast Unit between 2003 and 2013. Patients were divided into 3 subgroups based on p53 IHC expression: null (0%), low (0.1%-49%), and high (≥50%) p53 expression. Results: A total of 1387 patients were included in the study with a median follow-up of 86 months. After adjusting for age, size, node status, lymphovascular invasion, progesterone, and Ki67 expression, only null p53 immunophenotype was associated with worse disease-free survival (DFS) (OR 1.74, 95% IC, 1.11-2.71, P = .015) and distant recurrence-free survival (DRFS) (OR 1.73, 95% IC, 1.04-2.90, P = .036). Null p53 impacted significantly DFS and DRFS also in patients with early breast cancer. Conclusions: p53 IHC expression affects survival and, thus can be a valuable tool in the management of patients with HR-positive/Her2-negative breast cancer


  • Aesthetic results following breast cancer surgery: A prospective study on 6515 cases from ten Italian Senonetwork breast centers

    by M. Serra, A. Quattrini Li, L. Cataliotti, E. Cianchetti, F. Corsi, R. De Vita, L. Fabiocchi, L. Fortunato, D. Friedman, M. Klinger, et al.


  • Open Access

    Locoregional Control After Breast Conserving Treatment in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer

    by Simone Zanotti, Alice Pellegrini, Andrea Sibilio, Maddalena Rocchi, Margherita Serra, Donatella Santini, Mario Taffurelli

    1. Abstract In the last decade Neoadjuvant Chemotherapy (NAC) has become more common for patients with operable breast cancer. Greatest advantage of this approach is that it can increase the proportion of patients who can be treated with Breast Conserving Therapy (BCT). This is a retrospective study of a prospective database regarding 573 patients, consecutively treated with BCT and ALND, among these 84 were treated with NAC. Primary end-point of this study was to evaluate long-term outcomes of patients treated with BCT after NAC. Secondarily we evaluated same outcomes in populations with comparable initial clinical stage; more over factors affecting the risk of developing a Locoregional Recurernce (LRR) were investigated. Incidence rate registered for LRR was 1/100 person per year for patients treated with adjuvant chemotherapy, while it is doubled in the NAC-group with 2/100 person per year. Ipsilateral breast tumour recurrences’ incidence rate was 1 IBTR per 100 persons per year in the first group and twice as much in the NAC-group. When considering only patients initially staged cT2, there is no significant difference in terms of outcome at 5 and 10 years. NAC shows equivalent outcomes compared to BCT and adjuvant chemotherapy especially when our case-series is analyzed by presenting clinical tumor stage, leading to satisfactory locoregional outcomes without affecting overall survival of patients, thus increasing considerably the rates of patients eligible for conservative treatment. 2. Keywords: Breast Cancer; Conservative Treatment; Locoregional Recurrences; Neoadjuvant Chemotherapy